A provider has indicated that a serotonin/norepinephrine reuptake inhibitor (SNRI) will be prescribed for a patient who is experiencing major depression. When conducting a pretreatment health history, the nurse learns that the patient has a recent history of alcohol abuse. Which SNRI would be contraindicated for this patient?

Acute changes in mental status accompanied by autonomic instability and neuromuscular abnormalities after initiation of serotonergic medications suggest a life-threatening condition, serotonin toxicity. Serotonin syndrome occurs due to excessive serotonergic activity in the central nervous system, often shortly after starting or increasing doses of SSRIs. Clinical features include agitation, confusion, hyperthermia, tremors, muscle rigidity, and autonomic dysregulation such as diaphoresis. Rapid recognition and immediate discontinuation of the causative agent are critical to prevent progression to severe toxicity or death.

Rationale:
A. Adding an MAOI is dangerous and would significantly worsen the condition. Monoamine oxidase inhibitors further increase serotonin levels and can precipitate severe, potentially fatal serotonin toxicity when combined with SSRIs. This contradicts safe management principles and would intensify symptoms such as hyperthermia, rigidity, and autonomic instability.

B. Decreasing the dose of fluoxetine is inappropriate in an acute toxic reaction. Serotonin syndrome is not dose-managed but requires immediate cessation of the offending agent. Dose reduction would still allow ongoing serotonergic excess and could delay critical intervention, increasing the risk of complications such as seizures or organ failure.

C. An allergic reaction is unlikely because the symptoms described are not consistent with histamine-mediated hypersensitivity. There is no evidence of urticaria, airway swelling, or anaphylaxis. Instead, the combination of agitation, tremor, hyperreflexia, and muscle spasms strongly indicates a toxic serotonergic state rather than an immunologic reaction.

D. Immediate discontinuation of Fluoxetine is the priority intervention in serotonin syndrome. Removing the serotonergic agent stops further accumulation of serotonin activity in the central nervous system. Supportive care, sedation, and close monitoring are also required to stabilize autonomic and neuromuscular symptoms and prevent progression to severe complications.

Therapeutic drug monitoring is essential when using lithium because it has a narrow therapeutic index and a high risk of toxicity. Plasma levels must be carefully maintained within a defined therapeutic range to ensure effectiveness in mood stabilization while preventing adverse effects. Levels are routinely checked to guide dosing and prevent accumulation. Toxic effects become more likely as serum concentrations rise above the safe threshold.

Rationale:
A. Lithium levels should generally be kept below 1.5 mEq/L because concentrations above this range are associated with toxicity. At higher levels, patients may develop neurologic, gastrointestinal, and cardiovascular symptoms that can rapidly progress to severe toxicity. Maintaining levels below this threshold reduces the risk of serious complications.

B. 0.4 mEq/L is below the therapeutic range and would likely be ineffective for mood stabilization in Lithium therapy. Subtherapeutic levels may result in poor control of manic or depressive symptoms and increase the risk of relapse.

C. 0.2 mEq/L is significantly below therapeutic levels and is insufficient for clinical efficacy. At this concentration, lithium would not provide adequate mood stabilization or prophylaxis against bipolar episodes. It is far under the expected therapeutic range.

D. 0.8 mEq/L represents a typical maintenance therapeutic level rather than a maximum limit. Lithium is often maintained between approximately 0.6–1.2 mEq/L depending on clinical indication and patient response. This reflects a target range, not an upper toxicity threshold.